4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The 22q11.2 deletion syndrome (22q11.2DS) is a neurodevelopmental disorder associated with a number of volumetric brain abnormalities. The syndrome is also associated with an increased risk for neuropsychiatric disorders including schizophrenia and autism spectrum disorder. An earlier meta-analysis showed reduced grey and white matter volumes in individuals with 22q11.2DS. Since this analysis was conducted, the number of studies has increased markedly, permitting more precise estimates of effects and more regions to be examined. Although 22q11.2DS is clinically heterogeneous, it is not known to what extent this heterogeneity is mirrored in neuroanatomy. The aim of this study was thus to investigate differences in mean brain volume and structural variability within regions, between 22q11.2DS and typically developing controls. We examined studies that reported measures of brain volume using MRI in PubMed, Web of Science, Scopus and PsycINFO from inception to 1 May 2019. Data were extracted from studies in order to calculate effect sizes representing case–control difference in mean volume, and in the variability of volume (as measured using the log variability ratio (lnVR) and coefficient of variation ratio (CVR)). We found significant overall decreases in mean volume in 22q11.2DS compared with control for: total brain ( g = −0.96; p < 0.001); total grey matter ( g = −0.81, p < 0.001); and total white matter ( g = −0.81; p < 0.001). There was also a significant overall reduction of mean volume in 22q11.2DS subjects compared with controls in frontal lobe ( g = −0.47; p < 0.001), temporal lobe ( g = −0.84; p < 0.001), parietal lobe ( g = −0.73; p = 0.053), cerebellum ( g = −1.25; p < 0.001) and hippocampus ( g = −0.90; p < 0.001). Significantly increased variability in 22q11.2DS individuals compared with controls was found only for the hippocampus (VR, 1.14; p = 0.036; CVR, 1.30; p < 0.001), and lateral ventricles (VR, 1.56; p = 0.004 ). The results support the notion that structural abnormalities in 22q11.2DS and schizophrenia are convergent, and also to some degree with findings in autism spectrum disorder. Finally, the increased variability seen in the hippocampus in 22q11.2DS may underlie some of the heterogeneity observed in the neuropsychiatric phenotype.

          Related collections

          Most cited references60

          • Record: found
          • Abstract: found
          • Article: not found

          Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.

          The dopamine system is unique among the brain's modulatory systems in that it has discrete projections to specific brain regions involved in motor behaviour, cognition and emotion. Dopamine neurons exhibit several activity patterns - including tonic and phasic firing - that are determined by a combination of endogenous pacemaker conductances and regulation by multiple afferent systems. Emerging evidence suggests that disruptions in these regulatory systems may underlie the pathophysiology of several psychiatric disorders, including schizophrenia and depression.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Quantifying the impact of between-study heterogeneity in multivariate meta-analyses

            Measures that quantify the impact of heterogeneity in univariate meta-analysis, including the very popular I 2 statistic, are now well established. Multivariate meta-analysis, where studies provide multiple outcomes that are pooled in a single analysis, is also becoming more commonly used. The question of how to quantify heterogeneity in the multivariate setting is therefore raised. It is the univariate R 2 statistic, the ratio of the variance of the estimated treatment effect under the random and fixed effects models, that generalises most naturally, so this statistic provides our basis. This statistic is then used to derive a multivariate analogue of I 2, which we call . We also provide a multivariate H 2 statistic, the ratio of a generalisation of Cochran's heterogeneity statistic and its associated degrees of freedom, with an accompanying generalisation of the usual I 2 statistic, . Our proposed heterogeneity statistics can be used alongside all the usual estimates and inferential procedures used in multivariate meta-analysis. We apply our methods to some real datasets and show how our statistics are equally appropriate in the context of multivariate meta-regression, where study level covariate effects are included in the model. Our heterogeneity statistics may be used when applying any procedure for fitting the multivariate random effects model. Copyright © 2012 John Wiley & Sons, Ltd.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              High rates of schizophrenia in adults with velo-cardio-facial syndrome.

              Velo-cardio-facial syndrome (VCFS), a syndrome characterized by an increased frequency of schizophrenia and bipolar disorder, is associated with small interstitial deletions of chromosome 22q11. We evaluated 50 adults with VCFS using a structured clinical interview (Schedules for Clinical Assessment in Neuropsychiatry or Psychiatric Assessment Schedule for Adults With Developmental Disability if IQ <50) to establish a DSM-IV diagnosis. The schizophrenia phenotype in individuals with VCFS and schizophrenia was compared with a matched series of individuals with schizophrenia and without VCFS (n = 12). The King's Schizotypy Questionnaire was administered to individuals with VCFS (n = 41), their first-degree relatives (n = 68), and a series of unrelated normal controls (n = 316). All individuals with VCFS deleted for the N25 probe (n = 48) were genotyped for a genetic polymorphism in the COMT gene that results in variations in enzymatic activity. Fifteen individuals with VCFS (30%) had a psychotic disorder, with 24% (n = 12) fulfilling DSM-IV criteria for schizophrenia. In addition, 6 (12%) had major depression without psychotic features. The individuals with schizophrenia had fewer negative symptoms and a relatively later age of onset compared with those with schizophrenia and without VCFS. We found no evidence that possession of the low-activity COMT allele was associated with schizophrenia in our sample of individuals with VCFS. The high prevalence of schizophrenia in this group suggests that chromosome 22q11 might harbor a gene or genes relevant to the etiology of schizophrenia in the wider population.
                Bookmark

                Author and article information

                Contributors
                maria.rogdaki@kcl.ac.uk
                Journal
                Mol Psychiatry
                Mol. Psychiatry
                Molecular Psychiatry
                Nature Publishing Group UK (London )
                1359-4184
                1476-5578
                10 January 2020
                10 January 2020
                2020
                : 25
                : 8
                : 1704-1717
                Affiliations
                [1 ]ISNI 0000 0001 2322 6764, GRID grid.13097.3c, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, , King’s College London, ; London, SE5 8AF UK
                [2 ]ISNI 0000 0001 2113 8111, GRID grid.7445.2, Psychiatric Imaging Group, MRC London Institute of Medical Sciences, , Imperial College, ; London, W12 0NN UK
                [3 ]ISNI 0000 0001 2322 6764, GRID grid.13097.3c, Department of Forensic and Neurodevelopmental Sciences, and the Sackler Institute for Translational Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, , King’s College, ; London, SE5 8AF UK
                [4 ]ISNI 0000 0001 0807 5670, GRID grid.5600.3, Cardiff University Brain Research Imaging Centre, School of Psychology, , Cardiff University, ; Cardiff, Wales CF24 4HQ UK
                [5 ]ISNI 0000000121901201, GRID grid.83440.3b, Division of Psychiatry, , UCL, ; Maple House, London, W1T 7NF UK
                [6 ]Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt am Main, Goethe-University Frankfurt am Main, Frankfurt, Germany
                [7 ]ISNI 0000 0001 2324 5535, GRID grid.415717.1, National Autism Unit, , Bethlem Royal Hospital, ; London, UK
                [8 ]ISNI 0000 0001 2322 6764, GRID grid.13097.3c, MRC Centre for Neurodevelopmental Disorders, , King’s College London, ; London, UK
                Author information
                http://orcid.org/0000-0003-2685-1789
                http://orcid.org/0000-0002-0464-2065
                http://orcid.org/0000-0003-1102-2566
                http://orcid.org/0000-0001-5065-625X
                http://orcid.org/0000-0002-6664-7451
                Article
                638
                10.1038/s41380-019-0638-3
                7387301
                31925327
                27b364c7-b65d-4d95-bc37-cfc6fc2e3b24
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 16 December 2018
                : 2 December 2019
                : 12 December 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/100004440, Wellcome Trust (Wellcome);
                Award ID: 200102/Z/15/Z
                Award ID: 094849/Z/10/Z)
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100012176, Maudsley Charity;
                Award ID: 666
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100000265, RCUK | Medical Research Council (MRC);
                Award ID: MC-A656-5QD30
                Award Recipient :
                Categories
                Review Article
                Custom metadata
                © Springer Nature Limited 2020

                Molecular medicine
                neuroscience,psychiatric disorders
                Molecular medicine
                neuroscience, psychiatric disorders

                Comments

                Comment on this article